Compositions of obeticholic acid and methods of use
The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
1. A method of treating nonalcoholic steatohepatitis (NASH) in a subject in need thereof, said method comprising administering to the subject a tablet comprising an intra-granular portion and an extra-granular portion, the intra-granular portion comprising obeticholic acid or a pharmaceutically acceptable salt or amino acid conjugate thereof in an amount of about 1 to about 50 mg, and one or more pharmaceutically acceptable excipients, and the extra-granular portion comprising one or more pharmaceutically acceptable excipients,
wherein at least one pharmaceutically acceptable excipient in the tablet has an alcohol content of less than about 6% (w/w),
wherein the amount is a starting dose, an adjusted dose or a re-adjusted dose; and
wherein the tablet is administered daily (QD), every other day (Q2D), once a week (QW), twice a week (BID), three times a week (TIW), once a month (QM), or twice a month (Q2M).
2. The method of claim 1 , wherein the amount is about 1 mg to about 25 mg.
3. The method of claim 1 , wherein the tablet comprises obeticholic acid.
4. The method of claim 1 wherein the starting dose is administered in a titration period.
5. The method of claim 4 , wherein the titration period comprises 1 to 6 months.
6. The method of claim 5 , wherein the titration period is 3 months or 6 months.
7. The method of claim 1 , wherein the amount is 25 mg, and the tablet is administered daily.
8. The method of claim 1 , wherein the amount is 10 mg, and the tablet is administered daily.
9. The method of claim 1 , wherein the amount is about 1 mg to about 5 mg, and the tablet is administered daily.
10. A method of treatingnonalcoholic steatohepatitis (NASH) in a subject in need thereof, said method comprising administering to the subject a tablet comprising obeticholic acid or a pharmaceutically acceptable salt or amino acid conjugate thereof in an amount of about 1 to about 50 mg, and one or more pharmaceutically acceptable excipients,
wherein the obeticholic acid or the pharmaceutically acceptable salt or amino acid conjugate thereof is in the form of jet-milled particles, and wherein at least 50% of the particles have a diameter of 200 μm or less;
wherein at least one pharmaceutically acceptable excipient in the tablet has an alcohol content of less than about 6% (w/w);
wherein the amount is a starting dose, an adjusted dose or a re-adjusted dose; and
wherein the tablet is administered daily (QD), every other day (Q2D), once a week (QW), twice a week (BID), three times a week (TIW), once a month (QM), or twice a month (Q2M).
11. The method of claim 10 , wherein the amount is about 1 mg to about 25 mg.
12. The method of claim 10 , wherein the tablet comprises obeticholic acid.
13. The method of claim 10 wherein the starting dose is administered in a titration period.
14. The method of claim 13 , wherein said titration period comprises 1 to 6 months.
15. The method of claim 14 , wherein said titration period is 3 months or 6 months.
16. The method of claim 10 , wherein the amount is 25 mg, and the tablet is administered daily.
17. The method of claim 10 , wherein the amount is 10 mg, and the tablet is administered daily.
18. The method of claim 10 , wherein the amount is about 1 mg to about 5 mg, and the tablet is administered daily.
19. A method of treating nonalcoholic steatohepatitis (NASH) in a subject need thereof, said method comprising administering to the subject a tablet comprising an intra-granular portion and an extra-granular portion, the intra-granular portion comprising obeticholic acid or a pharmaceutically acceptable salt or amino acid conjugate thereof in an amount of about 1 to about 50 mg, and one or more pharmaceutically acceptable excipients, and the extra-granular portion comprising one or more pharmaceutically acceptable excipients,
wherein the obeticholic acid or the pharmaceutically acceptable salt or amino acid conjugate thereof is in the form of jet-milled particles, and wherein at least 50% of the particles have a diameter of 200 μm or less;
wherein at least one pharmaceutically acceptable excipient in the tablet has an alcohol content of less than about 6% (w/w);
wherein the amount is a starting dose, an adjusted dose or a re-adjusted dose; and
wherein the tablet is administered daily (QD), every other day (Q2D), once a week (QW), twice a week (BID), three times a week (TIW), once a month (QM), or twice a month (Q2M).
20. The method of claim 19 , wherein the amount is 25 mg, and the tablet is administered daily.